联合检测PTH和NT-proBNP对急性心力衰竭患者临床诊断及预后的价值

摘要

cqvip:目的:探讨联合检测外周血中甲状旁腺激素(PTH)和N末端脑钠肽前体(NT-proBNP)对急性心力衰竭(AHF)患者的临床诊断和预后价值。方法:选择我院的AHF患者112例为AHF组,选择同期健康体检者100例为健康对照组;AHF组根据病情分为轻度心衰组(62例)和重度心衰组(50例);根据近期预后情况分为事件组(47例)和非事件组(65例)。分别检测并比较各组间血清PTH和血浆NT-proBNP的水平,及对AHF诊断的灵敏度和特异度。结果:与健康对照组比较,AHF组患者血清PTH[(46.45±10.42)ng/L比(86.24±15.68)ng/L]和血浆NT-proBNP[(420.45±68.73)ng/L比(2678.34±211.06)ng/L]水平显著升高(P均=0.001);与轻度心衰组比较,重度心衰组患者血清PTH[(66.47±10.65)ng/L比(82.06±11.86)ng/L]和血浆NT-proBNP[(2001.45±119.83)ng/L比(2607.34±118.53)ng/L]水平显著升高(P均=0.001);与非事件组比较,事件组患者血清PTH[(68.53±8.75)ng/L比(80.04±12.86)ng/L]和血浆NT-proBNP[(2116.66±119.79)ng/L比(2563.29±145.52)ng/L]水平显著升高(P均=0.001);与单纯PTH或NT-proBNP检测比较,PTH联合NT-proBNP检测对各组的灵敏度和特异度显著提高(P<0.05或<0.01)。结论:联合检测PTH和NT-proBNP对急性心力衰竭患者的病情和预后评估十分重要。